ACOGAlpha Cognition Inc. Common Stock
9.750USDMkt Cap: 212.33M $P/E: —3d ago
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development pro…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap212.33M $
Enterprise Value170.95M $
Revenue (TTM)15.26M $
Gross Profit8.30M $
Net Income (TTM)-20.67M $
Revenue/Share0.7420 USD
Last Price9.750 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees71
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.73
PEG—
EV/EBITDA-6.45
EV/Revenue11.20
P/S13.91
P/B3.39
EPS (TTM)-0.96
EPS (Forward)-0.62
52W Range
9.36053% of range10.10
52W High10.10 USD
52W Low9.360 USD
Profitability
Gross Margin81.26%
Oper. Margin-127.29%
EBITDA Margin-173.57%
Profit Margin-202.24%
ROE-33.06%
ROA-25.92%
Growth
Revenue Growth267.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.38M $
CapEx (TTM)293.49K $
FCF Margin-186.95%
FCF Yield-13.44%
Net Debt-41.38M $
Net Debt/EBITDA1.56
Balance Sheet
Debt/Equity—
Current Ratio9.03
Quick Ratio7.31
Book Value/Sh2.872 USD
Cash/Share1.900 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.00 USD
Upside (mean)+84.6%
Target Range12.00 USD – 21.00 USD
$12.00+84.6% to mean$21.00
# Analysts5
Ownership
Shares Out.21.78M
Float11.62M
Insiders5.28%
Institutions53.32%
Short Interest
Short Ratio1.9d
Short % Float1.06%
Short % Out.0.85%
Shares Short184.59K
Short (prev mo.)129.90K
Technical
SMA 507.995 (+21.9%)
SMA 2006.433 (+51.6%)
Beta2.23
S&P 52W Chg19.18%
Avg Vol (30d)294.21K
Avg Vol (10d)191.89K
Technical Indicators
RSI (14)66.6
MACD0.3459
MACD Signal0.3142
MACD Hist.+0.0316
BB Upper9.516 USD
BB Middle8.812 USD
BB Lower8.108 USD
BB Width15.98%
ATR (14)0.7413 USD
Vol Ratio (20d)2.38x